Last reviewed · How we verify
Agitation associated with Schizophrenia
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Zyprexa · Eli Lilly
- Geodon · Pfizer Inc.
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class. - Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Zyprexa · Washington University School of Medicine
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Agitation associated with Schizophrenia patent landscape — cliff calendar, originator estates, attackable patents
- Agitation associated with Schizophrenia treatment landscape brief
- Agitation associated with Schizophrenia treatment updates RSS
Frequently asked questions about Agitation associated with Schizophrenia
What drugs treat Agitation associated with Schizophrenia?
Tracked treatments include Abilify, Zyprexa, Geodon.
What is the treatment for Agitation associated with Schizophrenia?
Standard treatment for Agitation associated with Schizophrenia includes Abilify, Zyprexa, Geodon. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Agitation associated with Schizophrenia patent cliff · Agitation associated with Schizophrenia CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Zyprexa · Eli Lilly
- Treatment: Geodon · Pfizer Inc.
- Treatment: Abilify · Generic (originally Otsuka/BMS)
- Treatment: Zyprexa · Washington University School of Medicine
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing